Skip to main content
Chiome Bioscience Inc. logo

Chiome Bioscience Inc. — Investor Relations & Filings

Ticker · 4583 ISIN · JP3205350006 T Professional, scientific and technical activities
Open in API
Filings indexed 70 across all filing types
Latest filing 2021-03-26 Governance Information
Country JP Japan
Listing T 4583

About Chiome Bioscience Inc.

https://www.chiome.co.jp/

Chiome Bioscience Inc. is a clinical-stage biotechnology company specializing in the research and development of antibody-based therapeutics. The company leverages its proprietary ADLib® system, an innovative antibody generation technology, to discover and develop fully human monoclonal antibodies. Its primary mission is to address unmet medical needs by creating novel antibody drugs. The company's operations focus on the early stages of the drug discovery and development process, including initial research and early-phase clinical trials.

Recent filings

Filing Released Lang Actions
内部統制報告書－第17期(令和2年1月1日－令和2年12月31日)
Governance Information Classification · 1% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, scope, and evaluation results regarding internal controls over financial reporting. Since this is a specific regulatory filing required by law and does not fit into categories like 10-K (Annual Report) or ER (Earnings Release), it falls under the 'Regulatory Filings' category.
2021-03-26 Japanese
有価証券報告書－第17期(令和2年1月1日－令和2年12月31日)
Annual Report Classification · 1% confidence The document is a 'Yuka Shoken Hokokusho' (Annual Securities Report) for Chiome Bioscience Inc. for the fiscal year ending December 31, 2020. This is the Japanese equivalent of a 10-K, containing comprehensive financial statements, business descriptions, and management analysis. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2020
2021-03-26 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is filed under Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2020
2021-03-26 Japanese
四半期報告書－第17期第3四半期(令和2年7月1日－令和2年9月30日)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) for Chiome Bioscience Inc., covering the third quarter of the 17th fiscal period (July 1, 2020, to September 30, 2020). It contains detailed financial statements, management analysis, and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-10 Japanese
四半期報告書－第17期第2四半期(令和2年4月1日－令和2年6月30日)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) for Chiome Bioscience Inc., covering the period from April 1, 2020, to June 30, 2020. It contains detailed financial statements, management analysis (MDA), and corporate information as required by the Financial Instruments and Exchange Act of Japan. Since it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q2 2020
2020-08-11 Japanese
四半期報告書－第17期第1四半期(令和2年1月1日－令和2年3月31日)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) for Chiome Bioscience Inc., covering the period from January 1, 2020, to March 31, 2020. It contains detailed financial statements (Balance Sheet, etc.), management analysis, and regulatory disclosures required under the Financial Instruments and Exchange Act of Japan. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. Q1 2020
2020-05-15 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.